Form 4: Recursion Pharmaceuticals Director Dean Y. Li Acquires Shares Under Director Compensation Policy

Director Dean Y. Li acquired 1,592 shares of Recursion Pharmaceuticals' Class A Common Stock on July 1, 2024, under the company's Outside Director Compensation Policy.

Summary

• On July 1, 2024, Dean Y. Li, a director of Recursion Pharmaceuticals, acquired 1,592 shares of Class A Common Stock.
• The acquisition was made under the Issuer's Outside Director Compensation Policy.
• The price of the acquired shares was $0.
• Following the transaction, Dean Y. Li directly owns 73,778 shares.
• Dean Y. Li also indirectly owns 1,422,048 shares through the Dean Li and Ruth Li Revocable Trust, 1,269,796 shares through the Dean Y. Li GRAT, and 421,000 shares through the Dean Y. Li 2021 Family Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares under a compensation policy is generally a good sign, indicating alignment with shareholder interests. However, the impact is limited as it's a standard compensation practice.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• The Outside Director Compensation Policy aligns director interests with shareholder interests.

Industry Context

Director share acquisitions are common and often viewed positively by investors as they align management's interests with those of shareholders.

Comparison to Industry Standards

• Director compensation policies vary across the pharmaceutical industry.
• Some companies offer stock options, while others provide restricted stock units or direct share grants.
• The specific terms of Recursion Pharmaceuticals' Outside Director Compensation Policy would need to be compared to those of peer companies to assess its competitiveness.

Stakeholder Impact

• The share acquisition could have a slightly positive impact on shareholder sentiment.
• The acquisition has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates